Kang Wendi, Cao Xiaomeng, Luo Jianwei
Department of Diagnostic Radiology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Quant Imaging Med Surg. 2023 Oct 1;13(10):6668-6682. doi: 10.21037/qims-23-226. Epub 2023 Sep 4.
Early recurrence (ER) of hepatocellular carcinoma (HCC) is defined as recurrence that occurs within two years after resection. Our study aimed to determine the optimal peritumoral regions of interest (ROI) range by comparing the effect of multiple peritumoral radiomics ROIs on predicting ER of HCC, and to develop and validate a combined clinical-radiomics prediction model.
A total of 160 HCC patients were randomly divided into a training cohort (n=112) and a validation cohort (n=48). The intratumoral original ROI was outlined based on enhanced computed tomography images and then used as the base to sequentially extend outward 1-5 mm to form peritumoral ROI. We developed a logistic regression model to predict ER of HCC. The efficacy of different ROI prediction models was compared to determine the optimal ROI. The combined model divided the patients into a high-risk group and low-risk group.
Ninety-seven (60.6%) of the patients were ER; the remaining 63 (39.4%) were not ER. The area under the curve values and 95% confidence intervals for ROI 3 were 0.867 (0.802-0.933) and 0.807 (0.682-0.931) in the training and validation cohorts, respectively, and ROI 3 was identified as the optimal ROI. Multivariate logistic regression analysis determined microvascular invasion (MVI) (P=0.037) and alpha-fetoprotein (AFP) (P=0.013) to be independent risk factors for ER. The combined clinical-radiomic model containing the radiomics score, MVI, and AFP had the optimal predictive efficacy, with area under the curve values and 95% confidence intervals of 0.903 (0.848-0.957) and 0.830 (0.709-0.952) in the training and validation cohort, respectively. Subgroup analysis showed significantly ER predicted in the high-risk group than the low-risk group (P<0.001).
Peritumoral radiomics 3 mm range was determined as the optimal ROI in this study. The clinical-radiomics combined models can effectively stratify high- and low-risk patients for timely clinical treatment and decision making.
肝细胞癌(HCC)的早期复发(ER)定义为切除术后两年内发生的复发。我们的研究旨在通过比较多个瘤周放射组学感兴趣区域(ROI)对预测HCC早期复发的效果,确定最佳瘤周ROI范围,并开发和验证一个临床-放射组学联合预测模型。
共160例HCC患者被随机分为训练队列(n = 112)和验证队列(n = 48)。基于增强CT图像勾勒出瘤内原始ROI,然后以此为基础依次向外扩展1 - 5毫米以形成瘤周ROI。我们开发了一个逻辑回归模型来预测HCC的早期复发。比较不同ROI预测模型的疗效以确定最佳ROI。联合模型将患者分为高风险组和低风险组。
97例(60.6%)患者出现早期复发;其余63例(39.4%)未出现早期复发。训练队列和验证队列中,ROI 3的曲线下面积值及95%置信区间分别为0.867(0.802 - 0.933)和0.807(0.682 - 0.931),ROI 3被确定为最佳ROI。多因素逻辑回归分析确定微血管侵犯(MVI)(P = 0.037)和甲胎蛋白(AFP)(P = 0.013)是早期复发的独立危险因素。包含放射组学评分、MVI和AFP的临床-放射组学联合模型具有最佳预测效能,训练队列和验证队列中曲线下面积值及95%置信区间分别为0.903(0.848 - 0.957)和0.830(0.709 - 0.952)。亚组分析显示,高风险组的早期复发预测率显著高于低风险组(P < 0.001)。
本研究确定瘤周放射组学3毫米范围为最佳ROI。临床-放射组学联合模型可有效对高风险和低风险患者进行分层,以便及时进行临床治疗和决策。